<DOC>
	<DOCNO>NCT02549924</DOCNO>
	<brief_summary>Type 2 diabetes mellitus [ T2DM ] quickly become epidemic XXI century challenge global health . Estimates World Health Organization [ WHO ] indicate globally , 1995 date nearly triple number people live diabetes mellitus [ DM ] . Resveratrol extensively study regulator glucose antioxidant effect protect pancreatic β cell activation sirtuin -1 [ SIRT1 ] dependent deacetylase nicotinamide adenine diphosphate [ NAD ] . Therefore , important know effect resveratrol glycemic variability [ GV ] patient T2DM control metformin monotherapy base .</brief_summary>
	<brief_title>Effect Administration Resveratrol Glycemic Variability Individuals With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>The objective evaluate effect administration resveratrol GV individual T2DM inadequately control metformin , conduct double-blind trial , randomize , placebo control group , group 11 male female patient 30-60 year age T2DM inadequately control metformin [ 2000 mg / day glycosylated hemoglobin A1c ( A1C ) ≥ % 7 ] , body mass index [ BMI ] form 25.0 34.9 kg / m2 . Randomization determine receive intervention 8-week trial [ resveratrol capsule , 500 mg 3 time daily first bite meal approve placebo capsule ] , group also continue metformin . The clinical finding laboratory test include metabolic profile biosafety , make baseline 8 week . Body weight , body fat , BMI blood pressure determine initial final visit , likewise , plasma glucose concentration every hour record 72 hour continuous monitor system outpatient glucose [ MACG ] via iPro ™ 2 [ Medtronic MiniMed , Northridge ] system , mean amplitude glucose excursion [ MAGE ] calculate AUC glucose , serve assess GV . Adverse event adherence treatment document . Statistical analysis : Mann-Whitney U test , Wilcoxon Fisher exact test . It consider significance p &lt; 0.05 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Resveratrol</mesh_term>
	<criteria>BMI 25.034.9 kg/m2 Diagnosis T2DM Fasting plasma glucose &gt; 130 &lt; 250 mg/dl time scrutiny A1C 7 10 % Metformin monotherapy Written inform consent Women pregnant breastfeeding Untreated thyroid disease and/or uncontrolled hypertension [ ≥150 systolic diastolic ≥90 ] Consumption oral agent medication supplement , unlike metformin , proven property modify behavior glucose Total cholesterol &gt; 400 mg/dL Triglycerides ≥400 mg/dL Liver enzymes [ ALT AST ] twice normal range Glomerular filtration rate &lt; 60 mL/min [ CockcroftGault ]</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Resveratrol</keyword>
	<keyword>Glycemic Variability</keyword>
	<keyword>MAGE</keyword>
</DOC>